Galeterone +/− Gemcitabine for Pancreatic Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use other anti-cancer agents while participating. You also must not have received chemotherapy for at least 4 weeks before starting the trial.
What data supports the effectiveness of the drug Galeterone combined with Gemcitabine for pancreatic cancer?
Research shows that Galeterone, when combined with Gemcitabine, can significantly inhibit the growth and spread of pancreatic cancer cells in lab studies and reduce tumor growth in mice. This combination targets specific pathways that help cancer cells survive and resist treatment, making it a promising option for further development.12345
Is the combination of Galeterone and Gemcitabine safe for humans?
Gemcitabine is known to have a favorable side-effect profile, making it generally safe for use in humans. Galeterone, primarily studied for prostate cancer, is in phase III clinical development, indicating it has passed initial safety evaluations. However, specific safety data for the combination of Galeterone and Gemcitabine in humans is not provided in the available research.23678
What makes the drug combination of Galeterone and Gemcitabine unique for pancreatic cancer?
What is the purpose of this trial?
Assess the effectiveness of galeterone in advanced pancreatic adenocarcinoma
Research Team
Aaron Ciner, MD
Principal Investigator
University of Maryland, Baltimore
Eligibility Criteria
This trial is for adults over 18 with advanced pancreatic adenocarcinoma who have tried at least two other treatments without success. They must be able to take oral medication, have a life expectancy of more than 12 weeks, and agree to use effective contraception. People with controlled brain metastasis may join, but not those with HIV, recent major surgery or radiation therapy, certain heart conditions, uncontrolled blood pressure issues, or active severe infections.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive galeterone alone or in combination with gemcitabine for pancreatic cancer
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival and progression-free survival
Treatment Details
Interventions
- Galeterone
- Gemcitabine
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Maryland, Baltimore
Lead Sponsor